Oncology prior authorization at Highmark
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Highmark oncology PA at a glance
Highmark reviews oncology PA submissions against its medical policy library, with rules drawn primarily from NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium. Highmark-specific context: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.
Documentation packet — what to send
- Histologic diagnosis with ICD-10-CM code
- Stage at diagnosis + current line of therapy
- Biomarker test result with date and lab
- Prior systemic therapies tried, response, and reason for discontinuation
- Performance status (ECOG or KPS)
- NCCN-supported indication with version number
Common denial patterns to pre-empt
Patterns observed in oncology across payers, and where Highmark's book of business overlaps:
- Off-label use not in FDA label
- Step therapy on biosimilar before reference biologic
- Site-of-care reduction (home infusion vs hospital)
- Frequency or duration outside policy
- Companion diagnostic not documented (HER2, PD-L1, MSI, BRCA, etc.)
- Prior auth on biologics
Appeal angles when Highmark denies
- NCCN Compendium Category 1/2A citation for off-label support
- Pivotal trial citation by name with FDA approval date
- Genomic biomarker documentation (FoundationOne, Guardant360, MSK-IMPACT)
- Tumor board recommendation
Peer-to-peer prep
- Have the NCCN page reference open on screen (version + page #)
- Open the patient's biomarker report alongside the chart
- Lead with the FDA-approved indication; pivot to NCCN if at the edge of the label
- State the line of therapy explicitly (1L, 2L, 3L) — common point of P2P misunderstanding
Drug-specific PA criteria at Highmark
Deep dives on each drug's PA criteria at Highmark:
Frequently asked questions
What documentation does Highmark need for oncology prior authorizations?
Highmark's PA packet for oncology typically includes: Histologic diagnosis with ICD-10-CM code; Stage at diagnosis + current line of therapy; Biomarker test result with date and lab; Prior systemic therapies tried, response, and reason for discontinuation. NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium citations strengthen the submission.
What's the turnaround at Highmark?
Highmark standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which oncology drugs does Highmark most often PA-restrict?
Top targets in oncology: pembrolizumab, rituximab, trastuzumab, bevacizumab, nivolumab. Each follows the per-drug step therapy + documentation requirements published in Highmark's medical policy library.
How do I prep a peer-to-peer with Highmark in oncology?
Have the NCCN page reference open on screen (version + page #) Open the patient's biomarker report alongside the chart Have the policy URL and the patient's chart open before the call.
Generate a Oncology PA packet
Open ApprovalHelp — generate a oncology PA packet tailored to Highmark's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com